{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:02:12Z","timestamp":1789984932259,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1124\/dmd.109.030361","type":"journal-article","created":{"date-parts":[[2010,4,10]],"date-time":"2010-04-10T01:09:20Z","timestamp":1270861760000},"page":"1238-1245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile"],"prefix":"10.1016","volume":"38","author":[{"given":"Xiaohai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore M.","family":"Kamenecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.109.030361_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-4632.2009.03835.x","article-title":"Erlotinib-induced dermatologic side-effects","volume":"48","author":"Bovenschen","year":"2009","journal-title":"Int J Dermatol"},{"issue":"Suppl 1","key":"10.1124\/dmd.109.030361_bib2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.3816\/CLC.2006.s.009","article-title":"Managing dermatologic toxicities of epidermal growth factor receptor inhibitors","volume":"8","author":"Chou","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1124\/dmd.109.030361_bib3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1073\/pnas.81.5.1327","article-title":"N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen","volume":"81","author":"Dahlin","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.109.030361_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1021\/tx049741u","article-title":"Negative ion tandem mass spectrometry for the detection of glutathione conjugates","volume":"18","author":"Dieckhaus","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.109.030361_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/tx600260a","article-title":"Applying mechanisms of chemical toxicity to predict drug safety","volume":"20","author":"Guengerich","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.109.030361_bib6","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1158\/1078-0432.CCR-05-2235","article-title":"Effects of smoking on the pharmacokinetics of erlotinib","volume":"12","author":"Hamilton","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.109.030361_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1081\/DMR-200033494","article-title":"Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen\/nitrogen species, and mitochondrial permeability transition","volume":"36","author":"Hinson","year":"2004","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.109.030361_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/20024091064273","article-title":"Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung","volume":"32","author":"Hukkanen","year":"2002","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.109.030361_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/17425255.2.2.261","article-title":"Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy","volume":"2","author":"Khan","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.109.030361_bib10","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1124\/dmd.109.030361_bib11","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","article-title":"Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.109.030361_bib12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1124\/dmd.108.025932","article-title":"Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways","volume":"37","author":"Li","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030361_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","article-title":"Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers","volume":"34","author":"Ling","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.109.030361_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.07-0050","article-title":"Pulmonary toxicity associated with erlotinib","volume":"132","author":"Liu","year":"2007","journal-title":"Chest"},{"key":"10.1124\/dmd.109.030361_bib15","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cgh.2007.04.014","article-title":"Fulminant hepatic failure secondary to erlotinib","volume":"5","author":"Liu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/dmd.109.030361_bib16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.109.030361_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000112936","article-title":"Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva)","volume":"216","author":"L\u00fcbbe","year":"2008","journal-title":"Dermatology"},{"key":"10.1124\/dmd.109.030361_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2407-7-150","article-title":"Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer","volume":"7","author":"Makris","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1124\/dmd.109.030361_bib19","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.109.030361_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.trsl.2006.12.005","article-title":"Apoptosis in ibuprofen-induced Stevens-Johnson syndrome","volume":"149","author":"Neuman","year":"2007","journal-title":"Transl Res"},{"key":"10.1124\/dmd.109.030361_bib21","series-title":"Alkenes and Alkynes","author":"Ortiz de Montellano","year":"1985"},{"key":"10.1124\/dmd.109.030361_bib22","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1016\/S0021-9258(19)70669-3","article-title":"Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates","volume":"255","author":"Ortiz de Montellano","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.109.030361_bib23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0003-9861(81)90333-7","article-title":"Shift of the acetylenic hydrogen during chemical and enzymatic oxidation of the biphenylacetylene triple bond","volume":"209","author":"Ortiz de Montellano","year":"1981","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.109.030361_bib24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1345\/aph.1L468","article-title":"Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer","volume":"43","author":"Pellegrinotti","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.109.030361_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00498250802638155","article-title":"Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design","volume":"39","author":"Perloff","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.109.030361_bib26","first-page":"39","article-title":"Acute drug induced hepatitis due to erlotinib","volume":"8","author":"Ramanarayanan","year":"2007","journal-title":"JOP"},{"key":"10.1124\/dmd.109.030361_bib27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","article-title":"Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.109.030361_bib28","first-page":"191","article-title":"Erlotinib-induced acute hepatitis in a patient with pancreatic cancer","volume":"6","author":"Saif","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1124\/dmd.109.030361_bib29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.10-8-579","article-title":"Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa)","volume":"10","author":"Siegel-Lakhai","year":"2005","journal-title":"Oncologist"},{"key":"10.1124\/dmd.109.030361_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","article-title":"Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib","volume":"45","author":"Takano","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1124\/dmd.109.030361_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14656566.7.2.177","article-title":"A review of erlotinib and its clinical use","volume":"7","author":"Tang","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/dmd.109.030361_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.3.3.407","article-title":"Drug metabolite profiling and elucidation of drug-induced hepatotoxicity","volume":"3","author":"Tang","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.109.030361_bib33","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1289\/ehp.8861","article-title":"Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers","volume":"114","author":"Thum","year":"2006","journal-title":"Environ Health Perspect"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.109.030361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:50:33Z","timestamp":1739897433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624024188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0090955624024188"],"URL":"https:\/\/doi.org\/10.1124\/dmd.109.030361","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.109.030361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}